Arrowstreet Capital Limited Partnership Has $58.79 Million Holdings in AbbVie Inc. $ABBV

Arrowstreet Capital Limited Partnership decreased its position in shares of AbbVie Inc. (NYSE:ABBV) by 12.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 316,713 shares of the company’s stock after selling 45,182 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in AbbVie were worth $58,788,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABBV. Marshall & Sullivan Inc. WA acquired a new stake in shares of AbbVie during the second quarter valued at about $25,000. TD Capital Management LLC increased its stake in shares of AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares during the period. Spurstone Advisory Services LLC bought a new position in AbbVie in the 2nd quarter valued at approximately $28,000. Financial Gravity Companies Inc. bought a new position in AbbVie in the 2nd quarter valued at approximately $36,000. Finally, Bear Mountain Capital Inc. boosted its position in AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after buying an additional 173 shares during the period. Institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent research reports. Daiwa Capital Markets upgraded shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price target for the company in a research report on Thursday, August 7th. Wells Fargo & Company boosted their price objective on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. UBS Group raised their target price on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. BMO Capital Markets lifted their target price on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Finally, DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a research note on Tuesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $241.85.

AbbVie Stock Performance

ABBV stock opened at $228.68 on Friday. The firm has a market cap of $404.17 billion, a PE ratio of 173.24, a price-to-earnings-growth ratio of 1.24 and a beta of 0.36. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The stock has a 50-day moving average price of $228.19 and a 200-day moving average price of $207.90. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm’s revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.